Triple antithrombotic therapy in cardiac patients: More questions than answers

European Heart Journal

Volumn 35, Issue 4, 2014, Pages

  Moser, Martin ^a   Olivier, Christoph B ^a   Bode, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute coronary syndrome; Antithrombotic therapy; Atrial fibrillation; Platelets; Triple therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG ELUTING STENT; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS;

ACUTE CORONARY SYNDROME; ANTITHROMBOTIC THERAPY; ATRIAL FIBRILLATION; PLATELETS; TRIPLE THERAPY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; EMBOLISM; FIBRINOLYTIC AGENTS; GRAFT OCCLUSION, VASCULAR; HEMORRHAGE; HUMANS; INDIVIDUALIZED MEDICINE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINES AS TOPIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; VITAMIN K;

EID: 84893043024     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht461     Document Type: Review

References (56)

1. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007;9:1006-1023.
2. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marin F. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary-A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010;31:1311-1318.
3. Sarno G, Lagerqvist B, Frobert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Venetzanos D, James S. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: A report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012;33:606-613.
4. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
5. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
6. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
7. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabate M, Kim HS, DeWaha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-Analysis. Lancet 2012;379:1393-1402.
8. WijnsW, Kolh P, Danchin N, Di Mario C, FalkV, FolliguetT, Garg S, HuberK, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501-2555.
9. Kim B-K, Hong M-K, Shin D-H, Nam C-M, Kim J-S, Ko Y-G, Choi D, Kang T-S, Park B-E, Kang W-C, Lee S-H, Yoon J-H, Hong B-K, Kwon H-M, Jang Y. A new strategy for discontinuation of dual antiplatelet therapy: The RESET trial (REal Safety and Efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-1348.
10. Gwon HC, Hahn JY, ParkKW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, ChungWY, Choi YJ, Hur SH, Kwon HM, JeonDW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-513.
11. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: A meta-Analysis of randomized trials. Eur Heart J 2012;33:3078-3087.
12. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569-2619.
13. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, WijnsW, Zahger D, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S, Achenbach S, Badimon L, Bertrand M, Botker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
14. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-e425.
15. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR.Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-Analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-250.
16. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-Artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671.
17. Nguyen MC, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, Budaj A, GulbaDC, Allegrone J, Brieger D, Investigators G. Combining warfarin and antiplatelet therapy after coronary stenting in the global registry of acute coronary events: Is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007;28:1717-1722.
18. Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB, Smith SC Jr, Peterson ED, Becker RC. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registry. Am Heart J 2008;155:361-368.
19. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van''t Hof AW, Ten Berg JM. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An openlabel, randomised, controlled trial. Lancet 2013;381:1107-1115.
20. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
21. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. BMJ 2002;325:1022-1025.
22. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
23. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006;367:1903-1912.
24. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
25. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
26. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-992.
27. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA 2006;295:1519-1530.
28. Roy P, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R. Impact of 'nuisance' bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008;102: 1614-1617.
29. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, Valdes M, Lip GY. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51:818-825.
30. Ruiz-Nodar JM, Marin F, Sanchez-Paya J, Hurtado JA, Valencia-Martin J, Manzano-Fernandez S, Roldan V, Perez-Andreu V, Sogorb F, Valdes M, Lip GY. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 2009;30:932-939.
31. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA, Airaksinen TJ, Niemela M, Vahlberg T, Airaksinen KE. Safety and efficacy of combined antiplateletwarfarin therapy after coronary stenting. Eur Heart J 2007;28:726-732.
32. Sambola A, Ferreira-Gonzalez I, Angel J, Alfonso F, Maristany J, Rodriguez O, Bueno H, Lopez-Minguez JR, Zueco J, Fernandez-Aviles F, Roman AS, Prendergast B, Mainar V, Garcia-Dorado D, Tornos P. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: The MUSICA study. Heart 2009;95:1483-1488.
33. Gao F, Zhou YJ, Wang ZJ, YangSW, Nie B, Liu XL, Jia de A, Yan ZX. Meta-Analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol 2011;148: 96-101.
34. Zhao HJ, Zheng ZT, Wang ZH, Li SH, Zhang Y, Zhong M, ZhangW. 'Triple therapy' rather than 'triple threat': A meta-Analysis of the two antithrombotic regimens after stent implantation in patients receiving long-Term oral anticoagulant treatment. Chest 2011;139:260-270.
35. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-1441.
36. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study. Circulation 2012;126:1185-1193.
37. Sarafoff N, Ndrepepa G, Mehilli J, Dorrler K, Schulz S, Iijima R, Byrne R, Schomig A, Kastrati A. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008;264:472-480.
38. Ruiz-Nodar JM, Marin F, Roldan V, Valencia J, Manzano-Fernandez S, Caballero L, Hurtado JA, Sogorb F, Valdes M, LipGY. Should werecommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk scoré Circulation 2012;5:459-466.
39. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data. Lancet 2009;374:1967-1974.
40. Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008;40: 428-436.
41. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/ AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011;57:e101-e198.
42. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, GoAS, Hughes M, Spencer FA, Manning WJ, Halperin JL, LipGY. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012;141(Suppl. 2):e531S-e575S.
43. DewildeW, Berg JT. Design and rationale of the WOEST trial: What is the optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). Am Heart J 2009;158:713-718.
44. Sambola A. Test of efficacy and safety of the dual antiplatelet therapy compared to the combination of oral anticoagulant therapy + dual antiplatelet therapy in patients with atrial fibrillation with low-moderate risk submitted to coronary stent implantation. 2011. [cited 5 September 2012]. http://apps.who.int/trialsearch/ Trial.aspx?TrialID=NCT01141153.
45. Mehilli J, Kastrati A. Intracoronary stenting and antithrombotic regimen: Testing of a six-week versus a six-month clopidogrel treatment regimen in patients with concomitant aspirin and oral anticoagulant therapy following drug-eluting stenting. 2010. [cited 5 September 2012]. http://apps.who.int/ trialsearch/Trial.aspx?TrialID=NCT00776633.
46. Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: Insights from the PCI-CURE study. Eur Heart J 2009;30:900-907.
47. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, Sirbu V, Bass TA, Della Rovere F, Gavazzi A, Angiolillo DJ. Long-Term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008;102:1618-1623.
48. Abbott. Abbott's XIENCE PRIMETM and XIENCE Vw drug eluting stents receive indication in Europe for minimum three-month duration of dual anti-platelet therapy. 2012. [cited 7 September 2012]. http://www.abbott.com/news-media/ pressreleases/ abbotts-xience-prime-And-xience-v-drug-eluting-stents- receiveindication- in-europe-for-minimum-Th.htm.
49. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189.
50. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
51. Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A. Triple therapy with aspirin, prasugrel and vitamin K antagonists in patients with drug eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013;61:2060-2066.
52. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-2789.
53. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365: 699-708.
54. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, Sundstrom J. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: A systematic review and meta-Analysis. Eur Heart J 2013;34: 1670-1680.
55. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009;374: 29-38.
56. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, VerheugtFW, Gibson CM. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.